---
title: "Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Budget impact"
description: "Formulary evidence on Adrabetadex (Lembaz, VTS-270) in Infantile-onset Niemann-Pick disease type C: Budget impact. Topics: Summary: eligible population, comparator prices, and absence of a published price. 1 evidence topic quoted from 11 sources."
canonical: "https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/executive-summary/budget-impact"
published: "2026-11-19T12:08:36-05:00"
modified: "2026-11-19T12:08:36-05:00"
---

# Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Budget impact

<a id="heading-1.1.3"></a>

## 1.1.3 Budget Impact of Adrabetadex

<a id="topic-1.1.3-1"></a>

### Summary: eligible population, comparator prices, and absence of a published price

No budget impact model of adrabetadex (Lembaz) has been published, and no list price had been announced at approval; trade press reporting on the approval states that “List pricing for the new product has not yet been announced”.

- Eligible population: Beren Therapeutics states that approximately half of those living with NPC in the U.S., or 475 children, have infantile-onset NPC, and that approximately two-thirds of people with NPC in the U.S. remain undiagnosed. A United States database analysis identified 294 individuals with an NPC diagnosis among 308 million unique individuals (0.95 per million) and estimated 943 prevalent cases of NPC, or 2.9 cases per million people. The developer of arimoclomol estimates approximately 900 individuals with NPC in the United States, of whom approximately 300 to 350 have been diagnosed. In manufacturer filings with California, the estimated number of patients was 300 for Miplyffa (arimoclomol) and 200 for Aqneursa (levacetylleucine). Over the year from 4/1/24 to 3/31/25, 8 Oregon Health Plan members had a diagnosis indicating NPC in their medical claims.
- Comparator prices: the ICER Launch Price and Access Report (2026) gives an annual list price of $967,432.50 and a best annual net price estimate of $940,586.25 for Miplyffa, and an annual list price of $701,321.42 and a best annual net price estimate of $576,661.54 for Aqneursa. The wholesale acquisition cost of Miplyffa reported to Texas for 1 January 2026 was $40,185 to $106,020 across the 47 mg to 124 mg strengths, and that reported for Aqneursa was $14,526. An Oklahoma Medicaid review gives $691,718.40 per year for Aqneursa at the FDA approved maximum dose of 4 g per day.

Source: [Pharmaphorum LEMBAZ approval report (2026)](https://pharmaphorum.com/news/berens-niemann-pick-drug-lembaz-cleared-fda); [Beren Therapeutics LEMBAZ approval press release (2026)](https://www.berentx.com/news/beren-therapeutics-announces-us-fda-approval-of-lembaz/); [Beren Therapeutics test for NPC press release (2026)](https://www.berentx.com/news/beren-therapeutics-launches-test-for-npc-to-help-identify-people-with-niemann-pick-disease-type-c-who-remain-undiagnosed/); [Burton et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/34304992/); [Zevra Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1434647/000143464726000011/zvra-20251231.htm); [California Department of Health Care Access and Information Prescription Drugs Introduced to Market, MIPLYFFA (2026)](https://data.chhs.ca.gov/api/3/action/datastore_search_sql?sql=SELECT%20%22Manufacturer%20Name%22%2C%22NDC%20Number%22%2C%22Drug%20Product%20Description%22%2C%22Date%20Introduced%20to%20Market%22%2C%22WAC%20at%20Introduction%22%2C%22Estimated%20Number%20of%20Patients%22%20FROM%20%220e3afcfc-a5eb-41c6-a633-deaa2bfb5710%22%20WHERE%20%22Drug%20Product%20Description%22%20LIKE%20%27Miplyffa%25%27); [California Department of Health Care Access and Information Prescription Drugs Introduced to Market (2026)](https://data.chhs.ca.gov/api/3/action/datastore_search_sql?sql=SELECT%20%22Manufacturer%20Name%22%2C%22NDC%20Number%22%2C%22Drug%20Product%20Description%22%2C%22Date%20Introduced%20to%20Market%22%2C%22WAC%20at%20Introduction%22%2C%22Estimated%20Number%20of%20Patients%22%2C%22Breakthrough%20Therapy%20Indicator%22%2C%22Priority%20Review%20Indicator%22%2C%22General%20Comments%22%20FROM%20%220e3afcfc-a5eb-41c6-a633-deaa2bfb5710%22%20WHERE%20%22NDC%20Number%22%20%3D%20%2783853010101%27); [Oregon State University Drug Use Research and Management Program (2025)](https://www.orpdl.org/durm/meetings/meetingdocs/2025_12_04/archives/2025_12_04_NDE_NiemannPickC.pdf); [ICER Launch Price and Access Report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_2026_Launch-Price-and-Access-Final-Report_ForPublication-1.pdf); [Texas Department of State Health Services 2026 Annual WAC Report (2026)](https://www.dshs.texas.gov/sites/default/files/CP-TexasRX/files/2026-annual-wac-report_1026.xlsx); [Oklahoma Health Care Authority Drug Utilization Review Board packet (2025)](https://oklahoma.gov/content/dam/ok/en/okhca/docs/about/boards-and-committees/dur/2025/march/03122025%20DUR%20Packet.pdf)

## Related pages
- [Adrabetadex (Lembaz): Infantile-onset Niemann-Pick disease type C](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Terms and abbreviations](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/terms-and-abbreviations.md)
- [Adrabetadex (Lembaz): Infantile-onset Niemann-Pick disease type C](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/executive-summary) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/executive-summary.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Product information and disease description](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/product-information-and-disease-description.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Clinical evidence](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/clinical-evidence.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Economic information and modeling report](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/economics) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/economics.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: References](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/references) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/references.md)
